Skip to main content
Top
Published in: Clinical Rheumatology 9/2008

01-09-2008 | Case Report

Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect?

Authors: Eishi Miyazaki, Masaru Ando, Tetsujiro Fukami, Shin-ichi Nureki, Yoshinobu Eishi, Toshihide Kumamoto

Published in: Clinical Rheumatology | Issue 9/2008

Login to get access

Abstract

A 47-year-old female was diagnosed to have pulmonary, ocular, and nodular-type muscular sarcoidosis. Seven years later, nodules developed in all limb muscles. She received minocycline 200 mg daily, which resulted in an obvious reduction of the muscular sarcoidosis with a significant decrease in the serum angiotensin-converting enzyme level. Nine months later, the minocycline was discontinued, thus resulting in a rapid recurrence of the disease. The immediate readministration of minocycline again resulted in a prompt improvement. We detected Propionibacterium acnes within the granulomas in the affected muscle by an immunohistochemistry. More interestingly, we found a decrease in the circulating levels of interleukin-12 p40 and interferon-inducible protein-10 during the minocycline therapy. The minocycline therapy may be effective for sarcoidosis and the fact that the disease rapidly relapsed after discontinuation of the minocycline administration suggests that the mechanism of action in this case may be immunomodulating but not antimicrobial effect.
Literature
1.
go back to reference Bachelez H, Senet P, Candranel J et al (2001) The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137:69–73PubMed Bachelez H, Senet P, Candranel J et al (2001) The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137:69–73PubMed
2.
go back to reference Park DJJ, Woog JJ, Pulido JS et al (2007) Minocycline for the treatment of ocular and ocular adnexal sarcoidosis. Arch Ophthalmol 125:705–709PubMedCrossRef Park DJJ, Woog JJ, Pulido JS et al (2007) Minocycline for the treatment of ocular and ocular adnexal sarcoidosis. Arch Ophthalmol 125:705–709PubMedCrossRef
3.
go back to reference Ishige I, Usui Y, Takemura T et al (1999) Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 354:120–123PubMedCrossRef Ishige I, Usui Y, Takemura T et al (1999) Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 354:120–123PubMedCrossRef
4.
go back to reference Webster GF, Toso SM, Hegemann L (1994) Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Arch Dermatol 130:748–752PubMedCrossRef Webster GF, Toso SM, Hegemann L (1994) Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Arch Dermatol 130:748–752PubMedCrossRef
5.
go back to reference Thong YH, Ferrante A (1979) Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogue. Clin Exp Immunol 35:443–446PubMed Thong YH, Ferrante A (1979) Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogue. Clin Exp Immunol 35:443–446PubMed
6.
go back to reference Kremlev SG, Roberts RL, Palmer C (2004) Differential expression of chemokines and chemokine receptors during microglial activation and inhibition. J Neuroimmunol 149:1–9PubMedCrossRef Kremlev SG, Roberts RL, Palmer C (2004) Differential expression of chemokines and chemokine receptors during microglial activation and inhibition. J Neuroimmunol 149:1–9PubMedCrossRef
7.
go back to reference Agostini C, Cassatella M, Zambello R et al (1998) Involvement of the IP-10 chemokine in sarcoid granulomatous reaction. J Immunol 161:6413–6420PubMed Agostini C, Cassatella M, Zambello R et al (1998) Involvement of the IP-10 chemokine in sarcoid granulomatous reaction. J Immunol 161:6413–6420PubMed
8.
go back to reference Hata M, Sugisaki K, Miyazaki E et al (2007) Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical marker. Intern Med 46:1387–1393PubMedCrossRef Hata M, Sugisaki K, Miyazaki E et al (2007) Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical marker. Intern Med 46:1387–1393PubMedCrossRef
Metadata
Title
Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect?
Authors
Eishi Miyazaki
Masaru Ando
Tetsujiro Fukami
Shin-ichi Nureki
Yoshinobu Eishi
Toshihide Kumamoto
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-0903-3

Other articles of this Issue 9/2008

Clinical Rheumatology 9/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.